Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906536 | 0.72 | PDE5A (0.56) | KDM4EHPGD | |
| SCHEMBL4897910 | 0.71 | KDM4E (0.43) | PDE9APPARDLMNAPPARGPPARA | |
| SCHEMBL6366055 | 0.64 | PDE9A (0.51) | PDE9AMAPT | |
| SCHEMBL6840453 | 0.61 | L3MBTL1 (0.55) | PPARDLMNATP53THRBMAPT | |
| SCHEMBL13197099 | 0.60 | FBP1 (0.50) | PPARDLMNATP53THRBMAPT | |
| SCHEMBL28155818 | 0.60 | SMN1; SMN2 (0.51) | PPARDLMNATP53THRBMAPT | |
| SCHEMBL7693031 | 0.59 | ALOX5 (0.57) | PPARDLMNATP53THRBMAPT | |
| SCHEMBL6367359 | 0.59 | PDE9A (0.50) | PDE9ANPC1 | |
| SCHEMBL6366064 | 0.59 | GRIN1 (0.47) | PDE9ALMNA | |
| SCHEMBL1569202 | 0.58 | SMN1; SMN2 (0.53) | PPARDLMNATP53THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 12/4885PPARD 171/4885PIM1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.